Clinical Trial: Rituximab Combined With Chemotherapy in Burkitt`s Lymphoma
Study Status: Completed
Recruit Status: Completed
Study Type: Interventional
Official Title: Burkimab:Study Multicenter of Optimization of the Treatment of LLA-B and the Burkitt's Lymphoma in Adult Patients (From 15 Years Old)
Brief Summary:
The purpose of this clinical trial is to prove the efficacy of the following new regimen treatment:
- Administration of anti-CD20 (Rituximab) combined with chemotherapy.
- Combined treatment with high doses of methotrexate and high doses of cytarabine with conventional cytostatics (block C)
- Prophylactic administration of G-CSF after all chemotherapy cycles
- local irradiation after 6 cycle if CNS was affected or if there are residual tumour
Detailed Summary: Clinical Trial with a pharmaceutical speciality in new conditions to use.
Sponsor: PETHEMA Foundation
Current Primary Outcome: Determinate the efficacy of the administration of anti-CD20 (RITUXIMAB) combined with chemotherapy. [ Time Frame: 1 year ]
Original Primary Outcome: Determinate the efficacy of the administration of anti-CD20 (RITUXIMAB) combined with chemotherapy.
Current Secondary Outcome:
- Combined treatment with high doses of methotrexate and high doses of cytarabine with conventional cytostatics (block C) [ Time Frame: 1 year ]
- Prophylactic administration of G-CSF after all chemotherapy cycles [ Time Frame: 1 year ]
- local irradiation after 6 cycle if CNS was affected or if there are residual tumour [ Time Frame: 1 year ]
Original Secondary Outcome:
- Combined treatment with high doses of methotrexate and high doses of cytarabine with conventional cytostatics (block C)
- Prophylactic administration of G-CSF after all chemotherapy cycles
- local irradiation after 6 cycle if CNS was affected or if there are residual tumour
Information By: PETHEMA Foundation
Dates:
Date Received: October 13, 2006
Date Started: August 2006
Date Completion:
Last Updated: October 27, 2014
Last Verified: February 2013
